Signal Genetics Granted First European Patent for MyPRS

Signal Genetics, Inc.

today announced the grant of EU Patent Number 2537942 for its proprietary MyPRS® genetic test. The patent, which was published on September 23, 2015, covers the use of the Company's gene expression profiling assay to predict survival in multiple myeloma patients. With the patent in place, the Company plans to seek licensing opportunities with European partners in order to expand its global footprint for MyPRS®. Samuel D. Riccitelli, President and CEO of Signal Genetics, commented, "The grant of this patent by the European Patent Office is a key milestone for Signal as we seek to expand our presence outside of the United States. With this protection, we are well positioned to license MyPRS® to partners in several countries within the European Union and further aid physicians in their treatment of patients suffering from multiple myeloma. This is part of our long-term growth strategy to provide better access to our assay and expand our potential sources for revenue." About